Clinical features related to statin-associated muscle symptoms

Heather M. Ochs-Balcom, Ly Minh Nguyen, Changxing Ma, Paul J. Isackson, Jasmine A. Luzum, Joseph P. Kitzmiller, Mark Tarnopolsky, Michael Weisman, Lisa Christopher-Stine, Wendy Peltier, Robert L. Wortmann, Georgirene D. Vladutiu

Research output: Contribution to journalArticle

Abstract

Introduction: Statins reduce cardiovascular disease risk and are generally well tolerated, yet up to 0.5% of statin-treated patients develop incapacitating muscle symptoms including rhabdomyolysis. Our objective was to identify clinical factors related to statin-associated muscle symptoms (SAMS). Methods: Clinical and laboratory characteristics were evaluated in 748 statin-treated Caucasians (634 with SAMS and 114 statin-tolerant controls). Information was collected on statin type, concomitant drug therapies, muscle symptom history, comorbidities, and family history. Logistic regression was used to identify associations. Results: Individuals with SAMS were 3.6 times (odds ratio [OR] 3.60, 95% confidence interval [CI] 2.08-6.22) more likely than statin-tolerant controls to have a family history of heart disease. Additional associations included obesity (OR 3.08, 95% CI 1.18, 8.05), hypertension (OR 2.24, 95% CI 1.33, 3.77), smoking (OR 2.08, 95% CI 1.16, 3.74), and statin type. Discussion: Careful medical monitoring of statin-treated patients with the associated coexisting conditions may ultimately reduce muscle symptoms and lead to improved compliance. Muscle Nerve, 2019.

Original languageEnglish (US)
JournalMuscle and Nerve
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscles
Odds Ratio
Confidence Intervals
Rhabdomyolysis
Compliance
Comorbidity
Heart Diseases
Cardiovascular Diseases
Obesity
Logistic Models
Smoking
History

Keywords

  • muscle disease
  • rhabdomyolysis
  • risk factors
  • statin-associated muscle symptoms
  • statins

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Ochs-Balcom, H. M., Nguyen, L. M., Ma, C., Isackson, P. J., Luzum, J. A., Kitzmiller, J. P., ... Vladutiu, G. D. (Accepted/In press). Clinical features related to statin-associated muscle symptoms. Muscle and Nerve. https://doi.org/10.1002/mus.26397

Clinical features related to statin-associated muscle symptoms. / Ochs-Balcom, Heather M.; Nguyen, Ly Minh; Ma, Changxing; Isackson, Paul J.; Luzum, Jasmine A.; Kitzmiller, Joseph P.; Tarnopolsky, Mark; Weisman, Michael; Christopher-Stine, Lisa; Peltier, Wendy; Wortmann, Robert L.; Vladutiu, Georgirene D.

In: Muscle and Nerve, 01.01.2019.

Research output: Contribution to journalArticle

Ochs-Balcom, HM, Nguyen, LM, Ma, C, Isackson, PJ, Luzum, JA, Kitzmiller, JP, Tarnopolsky, M, Weisman, M, Christopher-Stine, L, Peltier, W, Wortmann, RL & Vladutiu, GD 2019, 'Clinical features related to statin-associated muscle symptoms', Muscle and Nerve. https://doi.org/10.1002/mus.26397
Ochs-Balcom HM, Nguyen LM, Ma C, Isackson PJ, Luzum JA, Kitzmiller JP et al. Clinical features related to statin-associated muscle symptoms. Muscle and Nerve. 2019 Jan 1. https://doi.org/10.1002/mus.26397
Ochs-Balcom, Heather M. ; Nguyen, Ly Minh ; Ma, Changxing ; Isackson, Paul J. ; Luzum, Jasmine A. ; Kitzmiller, Joseph P. ; Tarnopolsky, Mark ; Weisman, Michael ; Christopher-Stine, Lisa ; Peltier, Wendy ; Wortmann, Robert L. ; Vladutiu, Georgirene D. / Clinical features related to statin-associated muscle symptoms. In: Muscle and Nerve. 2019.
@article{e4fd4b3c03e942c49ae35aa5ed288d4c,
title = "Clinical features related to statin-associated muscle symptoms",
abstract = "Introduction: Statins reduce cardiovascular disease risk and are generally well tolerated, yet up to 0.5{\%} of statin-treated patients develop incapacitating muscle symptoms including rhabdomyolysis. Our objective was to identify clinical factors related to statin-associated muscle symptoms (SAMS). Methods: Clinical and laboratory characteristics were evaluated in 748 statin-treated Caucasians (634 with SAMS and 114 statin-tolerant controls). Information was collected on statin type, concomitant drug therapies, muscle symptom history, comorbidities, and family history. Logistic regression was used to identify associations. Results: Individuals with SAMS were 3.6 times (odds ratio [OR] 3.60, 95{\%} confidence interval [CI] 2.08-6.22) more likely than statin-tolerant controls to have a family history of heart disease. Additional associations included obesity (OR 3.08, 95{\%} CI 1.18, 8.05), hypertension (OR 2.24, 95{\%} CI 1.33, 3.77), smoking (OR 2.08, 95{\%} CI 1.16, 3.74), and statin type. Discussion: Careful medical monitoring of statin-treated patients with the associated coexisting conditions may ultimately reduce muscle symptoms and lead to improved compliance. Muscle Nerve, 2019.",
keywords = "muscle disease, rhabdomyolysis, risk factors, statin-associated muscle symptoms, statins",
author = "Ochs-Balcom, {Heather M.} and Nguyen, {Ly Minh} and Changxing Ma and Isackson, {Paul J.} and Luzum, {Jasmine A.} and Kitzmiller, {Joseph P.} and Mark Tarnopolsky and Michael Weisman and Lisa Christopher-Stine and Wendy Peltier and Wortmann, {Robert L.} and Vladutiu, {Georgirene D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/mus.26397",
language = "English (US)",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Clinical features related to statin-associated muscle symptoms

AU - Ochs-Balcom, Heather M.

AU - Nguyen, Ly Minh

AU - Ma, Changxing

AU - Isackson, Paul J.

AU - Luzum, Jasmine A.

AU - Kitzmiller, Joseph P.

AU - Tarnopolsky, Mark

AU - Weisman, Michael

AU - Christopher-Stine, Lisa

AU - Peltier, Wendy

AU - Wortmann, Robert L.

AU - Vladutiu, Georgirene D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Statins reduce cardiovascular disease risk and are generally well tolerated, yet up to 0.5% of statin-treated patients develop incapacitating muscle symptoms including rhabdomyolysis. Our objective was to identify clinical factors related to statin-associated muscle symptoms (SAMS). Methods: Clinical and laboratory characteristics were evaluated in 748 statin-treated Caucasians (634 with SAMS and 114 statin-tolerant controls). Information was collected on statin type, concomitant drug therapies, muscle symptom history, comorbidities, and family history. Logistic regression was used to identify associations. Results: Individuals with SAMS were 3.6 times (odds ratio [OR] 3.60, 95% confidence interval [CI] 2.08-6.22) more likely than statin-tolerant controls to have a family history of heart disease. Additional associations included obesity (OR 3.08, 95% CI 1.18, 8.05), hypertension (OR 2.24, 95% CI 1.33, 3.77), smoking (OR 2.08, 95% CI 1.16, 3.74), and statin type. Discussion: Careful medical monitoring of statin-treated patients with the associated coexisting conditions may ultimately reduce muscle symptoms and lead to improved compliance. Muscle Nerve, 2019.

AB - Introduction: Statins reduce cardiovascular disease risk and are generally well tolerated, yet up to 0.5% of statin-treated patients develop incapacitating muscle symptoms including rhabdomyolysis. Our objective was to identify clinical factors related to statin-associated muscle symptoms (SAMS). Methods: Clinical and laboratory characteristics were evaluated in 748 statin-treated Caucasians (634 with SAMS and 114 statin-tolerant controls). Information was collected on statin type, concomitant drug therapies, muscle symptom history, comorbidities, and family history. Logistic regression was used to identify associations. Results: Individuals with SAMS were 3.6 times (odds ratio [OR] 3.60, 95% confidence interval [CI] 2.08-6.22) more likely than statin-tolerant controls to have a family history of heart disease. Additional associations included obesity (OR 3.08, 95% CI 1.18, 8.05), hypertension (OR 2.24, 95% CI 1.33, 3.77), smoking (OR 2.08, 95% CI 1.16, 3.74), and statin type. Discussion: Careful medical monitoring of statin-treated patients with the associated coexisting conditions may ultimately reduce muscle symptoms and lead to improved compliance. Muscle Nerve, 2019.

KW - muscle disease

KW - rhabdomyolysis

KW - risk factors

KW - statin-associated muscle symptoms

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=85059857681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059857681&partnerID=8YFLogxK

U2 - 10.1002/mus.26397

DO - 10.1002/mus.26397

M3 - Article

C2 - 30549046

AN - SCOPUS:85059857681

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

ER -